{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:02:24Z","timestamp":1789606944957,"version":"build-2803163510"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":42,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100007202","name":"Gouvernement du Canada | Instituts de Recherche en Sant\u00e9 du Canada | CIHR Skin Research Training Centre","doi-asserted-by":"publisher","award":["158225"],"award-info":[{"award-number":["158225"]}],"id":[{"id":"10.13039\/501100007202","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007202","name":"Gouvernement du Canada | Instituts de Recherche en Sant\u00e9 du Canada | CIHR Skin Research Training Centre","doi-asserted-by":"publisher","award":["168933"],"award-info":[{"award-number":["168933"]}],"id":[{"id":"10.13039\/501100007202","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-76385-8","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T07:54:53Z","timestamp":1786002893000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A chromatin-informed transcriptional regulatory framework to stratify patients and guide therapy selection in triple-negative breast cancer"],"prefix":"10.1038","volume":"17","author":[{"given":"Shalini","family":"Bahl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nergiz","family":"Dogan-Artun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4715-5150","authenticated-orcid":false,"given":"Julia","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wail","family":"Ba-alawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Ali","family":"Madani Tonekaboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Komaldeep Kaur","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"McGuire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Tobin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Silvester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2881-6717","authenticated-orcid":false,"given":"Paul","family":"Savage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6540-001X","authenticated-orcid":false,"given":"Lucie","family":"Cressot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7071-5114","authenticated-orcid":false,"given":"Ankita","family":"Nand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanqiao","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Guilhamon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8510-7963","authenticated-orcid":false,"given":"Arvind Singh","family":"Mer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Arlidge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6711-7287","authenticated-orcid":false,"given":"Mitchell J.","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5400-606X","authenticated-orcid":false,"given":"Morag","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1080-0998","authenticated-orcid":false,"given":"David W.","family":"Cescon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Haibe-Kains","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0929-9478","authenticated-orcid":false,"given":"Mathieu","family":"Lupien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"key":"76385_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-019-1210-4","volume":"21","author":"CH Li","year":"2019","unstructured":"Li, C. H., Karantza, V., Aktan, G. & Lala, M. Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review. Breast Cancer Res. 21, 143 (2019).","journal-title":"Breast Cancer Res."},{"key":"76385_CR2","first-page":"477","volume":"74","author":"AN Giaquinto","year":"2024","unstructured":"Giaquinto, A. N. et al. Breast cancer statistics 2024. CA Cancer J. Clin. 74, 477\u2013495 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"76385_CR3","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel, R. L., Kratzer, T. B., Giaquinto, A. N., Sung, H. & Jemal, A. Cancer statistics, 2025. CA Cancer J. Clin. 75, 10\u201345 (2025).","journal-title":"CA Cancer J. Clin."},{"key":"76385_CR4","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1200\/JCO.22.02572","volume":"41","author":"C Liedtke","year":"2023","unstructured":"Liedtke, C. et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J. Clin. Oncol. 41, 1809\u20131815 (2023).","journal-title":"J. Clin. Oncol."},{"key":"76385_CR5","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1056\/NEJMra1001389","volume":"363","author":"WD Foulkes","year":"2010","unstructured":"Foulkes, W. D., Smith, I. E. & Reis-Filho, J. S. Triple-negative breast cancer. N. Engl. J. Med. 363, 1938\u20131948 (2010).","journal-title":"N. Engl. J. Med."},{"key":"76385_CR6","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.1200\/JCO.22.02864","volume":"41","author":"AC Wolff","year":"2023","unstructured":"Wolff, A. C. et al. Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American Pathologists guideline update. J. Clin. Oncol. 41, 3867\u20133872 (2023).","journal-title":"J. Clin. Oncol."},{"key":"76385_CR7","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1200\/JCO.19.02309","volume":"38","author":"KH Allison","year":"2020","unstructured":"Allison, K. H. et al. Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update. J. Clin. Oncol. 38, 1346\u20131366 (2020).","journal-title":"J. Clin. Oncol."},{"key":"76385_CR8","doi-asserted-by":"publisher","first-page":"161","DOI":"10.3747\/co.v18i4.824","volume":"18","author":"J Lachapelle","year":"2011","unstructured":"Lachapelle, J. & Foulkes, W. D. Triple-negative and basal-like breast cancer: implications for oncologists. Curr. Oncol. 18, 161\u2013164 (2011).","journal-title":"Curr. Oncol."},{"key":"76385_CR9","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.cell.2018.03.041","volume":"173","author":"C Kim","year":"2018","unstructured":"Kim, C. et al. Chemoresistance evolution in triple-negative breast cancer delineated by single-cell sequencing. Cell 173, 879\u2013893.e13 (2018).","journal-title":"Cell"},{"key":"76385_CR10","doi-asserted-by":"publisher","first-page":"e071674","DOI":"10.1136\/bmj-2022-071674","volume":"381","author":"RA Leon-Ferre","year":"2023","unstructured":"Leon-Ferre, R. A. & Goetz, M. P. Advances in systemic therapies for triple negative breast cancer. BMJ 381, e071674 (2023).","journal-title":"BMJ"},{"key":"76385_CR11","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/S1470-2045(10)70257-6","volume":"11","author":"J Cuzick","year":"2010","unstructured":"Cuzick, J. et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 11, 1135\u20131141 (2010).","journal-title":"Lancet Oncol."},{"key":"76385_CR12","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","volume":"378","author":"Early","year":"2011","unstructured":"Early et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378, 771\u2013784 (2011).","journal-title":"Lancet"},{"key":"76385_CR13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","volume":"42","author":"F Meric-Bernstam","year":"2024","unstructured":"Meric-Bernstam, F. et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J. Clin. Oncol. 42, 47\u201358 (2024).","journal-title":"J. Clin. Oncol."},{"key":"76385_CR14","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","volume":"13","author":"G Bianchini","year":"2016","unstructured":"Bianchini, G., Balko, J. M., Mayer, I. A., Sanders, M. E. & Gianni, L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat. Rev. Clin. Oncol. 13, 674\u2013690 (2016).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"76385_CR15","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1158\/2159-8290.CD-18-1177","volume":"9","author":"AC Garrido-Castro","year":"2019","unstructured":"Garrido-Castro, A. C., Lin, N. U. & Polyak, K. Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov. 9, 176\u2013198 (2019).","journal-title":"Cancer Discov."},{"key":"76385_CR16","doi-asserted-by":"publisher","first-page":"a041322","DOI":"10.1101\/cshperspect.a041322","volume":"12","author":"S Bahl","year":"2022","unstructured":"Bahl, S., Carroll, J. S. & Lupien, M. Chromatin variants reveal the genetic determinants of oncogenesis in breast cancer. Cold Spring Harb. Perspect. Med. 12, a041322 (2022).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"76385_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-08916-0","author":"L Mahendrawada","year":"2025","unstructured":"Mahendrawada, L., Warfield, L., Donczew, R. & Hahn, S. Low overlap of transcription factor DNA binding and regulatory targets. Nature https:\/\/doi.org\/10.1038\/s41586-025-08916-0 (2025).","journal-title":"Nature"},{"key":"76385_CR18","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.cell.2016.12.013","volume":"168","author":"JE Bradner","year":"2017","unstructured":"Bradner, J. E., Hnisz, D. & Young, R. A. Transcriptional addiction in cancer. Cell 168, 629\u2013643 (2017).","journal-title":"Cell"},{"key":"76385_CR19","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/nature11232","volume":"489","author":"RE Thurman","year":"2012","unstructured":"Thurman, R. E. et al. The accessible chromatin landscape of the human genome. Nature 489, 75\u201382 (2012).","journal-title":"Nature"},{"key":"76385_CR20","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/s41586-020-2559-3","volume":"584","author":"W Meuleman","year":"2020","unstructured":"Meuleman, W. et al. Index and biological spectrum of human DNase I hypersensitive sites. Nature 584, 244\u2013251 (2020).","journal-title":"Nature"},{"key":"76385_CR21","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.cell.2013.07.020","volume":"154","author":"AB Stergachis","year":"2013","unstructured":"Stergachis, A. B. et al. Developmental fate and cellular maturity encoded in human regulatory DNA landscapes. Cell 154, 888\u2013903 (2013).","journal-title":"Cell"},{"key":"76385_CR22","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Network Comprehensive molecular portraits of human breast tumours. Nature 490, 61\u201370 (2012).","DOI":"10.1038\/nature11412"},{"key":"76385_CR23","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1093\/bioinformatics\/btv693","volume":"32","author":"DMA Gendoo","year":"2016","unstructured":"Gendoo, D. M. A. et al. Genefu: an R\/Bioconductor package for computation of gene expression-based signatures in breast cancer. Bioinformatics 32, 1097\u20131099 (2016).","journal-title":"Bioinformatics"},{"key":"76385_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-7-S1-S7","volume":"7","author":"AA Margolin","year":"2006","unstructured":"Margolin, A. A. et al. ARACNE: an algorithm for the reconstruction of gene regulatory networks in a mammalian cellular context. BMC Bioinforma. 7, S7 (2006).","journal-title":"BMC Bioinforma."},{"key":"76385_CR25","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1093\/bioinformatics\/btw216","volume":"32","author":"A Lachmann","year":"2016","unstructured":"Lachmann, A., Giorgi, F. M., Lopez, G. & Califano, A. ARACNe-AP: gene network reverse engineering through adaptive partitioning inference of mutual information. Bioinformatics 32, 2233\u20132235 (2016).","journal-title":"Bioinformatics"},{"key":"76385_CR26","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/ng.3593","volume":"48","author":"MJ Alvarez","year":"2016","unstructured":"Alvarez, M. J. et al. Functional characterization of somatic mutations in cancer using network-based inference of protein activity. Nat. Genet. 48, 838\u2013847 (2016).","journal-title":"Nat. Genet."},{"key":"76385_CR27","doi-asserted-by":"publisher","DOI":"10.1126\/science.aav1898","volume":"362","author":"MR Corces","year":"2018","unstructured":"Corces, M. R. et al. The chromatin accessibility landscape of primary human cancers. Science 362, eaav1898 (2018).","journal-title":"Science"},{"key":"76385_CR28","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature10983","volume":"486","author":"C Curtis","year":"2012","unstructured":"Curtis, C. et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486, 346\u2013352 (2012).","journal-title":"Nature"},{"key":"76385_CR29","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/s41576-019-0209-0","volume":"21","author":"M Gasperini","year":"2020","unstructured":"Gasperini, M., Tome, J. M. & Shendure, J. Towards a comprehensive catalogue of validated and target-linked human enhancers. Nat. Rev. Genet. 21, 292\u2013310 (2020).","journal-title":"Nat. Rev. Genet."},{"key":"76385_CR30","doi-asserted-by":"publisher","first-page":"D174","DOI":"10.1093\/nar\/gkad1059","volume":"52","author":"I Rauluseviciute","year":"2024","unstructured":"Rauluseviciute, I. et al. JASPAR 2024: 20th anniversary of the open-access database of transcription factor binding profiles. Nucleic Acids Res. 52, D174\u2013D182 (2024).","journal-title":"Nucleic Acids Res."},{"key":"76385_CR31","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1016\/j.cell.2014.08.009","volume":"158","author":"MT Weirauch","year":"2014","unstructured":"Weirauch, M. T. et al. Determination and inference of eukaryotic transcription factor sequence specificity. Cell 158, 1431\u20131443 (2014).","journal-title":"Cell"},{"key":"76385_CR32","doi-asserted-by":"publisher","first-page":"3547","DOI":"10.1016\/j.celrep.2019.05.004","volume":"27","author":"MC Cuiti\u00f1o","year":"2019","unstructured":"Cuiti\u00f1o, M. C. et al. Two distinct E2F transcriptional modules drive cell cycles and differentiation. Cell Rep. 27, 3547\u20133560.e5 (2019).","journal-title":"Cell Rep."},{"key":"76385_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11479","volume":"7","author":"B Pereira","year":"2016","unstructured":"Pereira, B. et al. The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nat. Commun. 7, 11479 (2016).","journal-title":"Nat. Commun."},{"key":"76385_CR34","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.cell.2018.02.052","volume":"173","author":"J Liu","year":"2018","unstructured":"Liu, J. et al. An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell 173, 400\u2013416.e11 (2018).","journal-title":"Cell"},{"key":"76385_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/sdata.2017.166","volume":"4","author":"M Hafner","year":"2017","unstructured":"Hafner, M. et al. Quantification of sensitivity and resistance of breast cancer cell lines to anti-cancer drugs using GR metrics. Sci. Data 4, 170166 (2017).","journal-title":"Sci. Data"},{"key":"76385_CR36","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cell.2016.06.017","volume":"166","author":"F Iorio","year":"2016","unstructured":"Iorio, F. et al. A landscape of pharmacogenomic interactions in cancer. Cell 166, 740\u2013754 (2016).","journal-title":"Cell"},{"key":"76385_CR37","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1158\/2159-8290.CD-15-0235","volume":"5","author":"B Seashore-Ludlow","year":"2015","unstructured":"Seashore-Ludlow, B. et al. Harnessing connectivity in a large-scale small-molecule sensitivity dataset. Cancer Discov. 5, 1210\u20131223 (2015).","journal-title":"Cancer Discov."},{"key":"76385_CR38","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1093\/bioinformatics\/btv723","volume":"32","author":"P Smirnov","year":"2016","unstructured":"Smirnov, P. et al. PharmacoGx: an R package for analysis of large pharmacogenomic datasets. Bioinformatics 32, 1244\u20131246 (2016).","journal-title":"Bioinformatics"},{"key":"76385_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25974-w","volume":"12","author":"A Mammoliti","year":"2021","unstructured":"Mammoliti, A. et al. Orchestrating and sharing large multimodal data for transparent and reproducible research. Nat. Commun. 12, 5797 (2021).","journal-title":"Nat. Commun."},{"key":"76385_CR40","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.semcancer.2019.07.009","volume":"59","author":"AS Alzahrani","year":"2019","unstructured":"Alzahrani, A. S. PI3K\/Akt\/mTOR inhibitors in cancer: at the bench and bedside. Semin. Cancer Biol. 59, 125\u2013132 (2019).","journal-title":"Semin. Cancer Biol."},{"key":"76385_CR41","doi-asserted-by":"publisher","first-page":"4539","DOI":"10.1158\/0008-5472.CAN-19-0349","volume":"79","author":"AS Mer","year":"2019","unstructured":"Mer, A. S. et al. Integrative pharmacogenomics analysis of patient-derived xenografts. Cancer Res. 79, 4539\u20134550 (2019).","journal-title":"Cancer Res."},{"key":"76385_CR42","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1101\/gad.176826.111","volume":"25","author":"KS Zaret","year":"2011","unstructured":"Zaret, K. S. & Carroll, J. S. Pioneer transcription factors: establishing competence for gene expression. Genes Dev. 25, 2227\u20132241 (2011).","journal-title":"Genes Dev."},{"key":"76385_CR43","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/nbt.2798","volume":"32","author":"RI Sherwood","year":"2014","unstructured":"Sherwood, R. I. et al. Discovery of directional and nondirectional pioneer transcription factors by modeling DNase profile magnitude and shape. Nat. Biotechnol. 32, 171\u2013178 (2014).","journal-title":"Nat. Biotechnol."},{"key":"76385_CR44","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41576-018-0089-8","volume":"20","author":"SL Klemm","year":"2019","unstructured":"Klemm, S. L., Shipony, Z. & Greenleaf, W. J. Chromatin accessibility and the regulatory epigenome. Nat. Rev. Genet. 20, 207\u2013220 (2019).","journal-title":"Nat. Rev. Genet."},{"key":"76385_CR45","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/nature10730","volume":"481","author":"CS Ross-Innes","year":"2012","unstructured":"Ross-Innes, C. S. et al. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 481, 389\u2013393 (2012).","journal-title":"Nature"},{"key":"76385_CR46","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13072-015-0009-5","volume":"8","author":"N Dogan","year":"2015","unstructured":"Dogan, N. et al. Occupancy by key transcription factors is a more accurate predictor of enhancer activity than histone modifications or chromatin accessibility. Epigenetics Chromatin 8, 16 (2015).","journal-title":"Epigenetics Chromatin"},{"key":"76385_CR47","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","volume":"377","author":"H Pan","year":"2017","unstructured":"Pan, H. et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N. Engl. J. Med. 377, 1836\u20131846 (2017).","journal-title":"N. Engl. J. Med."},{"key":"76385_CR48","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia, A. et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N. Engl. J. Med. 384, 1529\u20131541 (2021).","journal-title":"N. Engl. J. Med."},{"key":"76385_CR49","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1172\/JCI45014","volume":"121","author":"BD Lehmann","year":"2011","unstructured":"Lehmann, B. D. et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Invest. 121, 2750\u20132767 (2011).","journal-title":"J. Clin. Invest."},{"key":"76385_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26502-6","volume":"12","author":"BD Lehmann","year":"2021","unstructured":"Lehmann, B. D. et al. Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes. Nat. Commun. 12, 6276 (2021).","journal-title":"Nat. Commun."},{"key":"76385_CR51","doi-asserted-by":"publisher","first-page":"333","DOI":"10.3389\/fgene.2020.00333","volume":"11","author":"H Chen","year":"2020","unstructured":"Chen, H. et al. Transcription factor profiling to predict recurrence-free survival in breast cancer: development and validation of a nomogram to optimize clinical management. Front. Genet. 11, 333 (2020).","journal-title":"Front. Genet."},{"key":"76385_CR52","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s12282-018-0842-z","volume":"25","author":"F Omata","year":"2018","unstructured":"Omata, F. et al. Effect of the normal mammary differentiation regulator ELF5 upon clinical outcomes of triple negative breast cancers patients. Breast Cancer 25, 489\u2013496 (2018).","journal-title":"Breast Cancer"},{"key":"76385_CR53","doi-asserted-by":"publisher","first-page":"21938","DOI":"10.18632\/oncotarget.15749","volume":"8","author":"L Min","year":"2017","unstructured":"Min, L. et al. Gene regulatory pattern analysis reveals essential role of core transcriptional factors\u2019 activation in triple-negative breast cancer. Oncotarget 8, 21938\u201321953 (2017).","journal-title":"Oncotarget"},{"key":"76385_CR54","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2202809","volume":"387","author":"J Cortes","year":"2022","unstructured":"Cortes, J. et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N. Engl. J. Med. 387, 217\u2013226 (2022).","journal-title":"N. Engl. J. Med."},{"key":"76385_CR55","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1007\/s12282-023-01451-8","volume":"30","author":"H Yamauchi","year":"2023","unstructured":"Yamauchi, H. et al. Adjuvant olaparib in the subset of patients from Japan with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial. Breast Cancer 30, 596\u2013605 (2023).","journal-title":"Breast Cancer"},{"key":"76385_CR56","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","volume":"384","author":"ANJ Tutt","year":"2021","unstructured":"Tutt, A. N. J. et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N. Engl. J. Med. 384, 2394\u20132405 (2021).","journal-title":"N. Engl. J. Med."},{"key":"76385_CR57","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1056\/NEJMoa2511734","volume":"393","author":"J Cort\u00e9s","year":"2025","unstructured":"Cort\u00e9s, J. et al. Sacituzumab govitecan in untreated, advanced triple-negative breast cancer. N. Engl. J. Med. 393, 1912\u20131925 (2025).","journal-title":"N. Engl. J. Med."},{"key":"76385_CR58","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJMoa2508959","volume":"394","author":"SM Tolaney","year":"2026","unstructured":"Tolaney, S. M. et al. Sacituzumab govitecan plus pembrolizumab for advanced triple-negative breast cancer. N. Engl. J. Med. 394, 354\u2013366 (2026).","journal-title":"N. Engl. J. Med."},{"key":"76385_CR59","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3892\/ol.2023.14030","volume":"26","author":"W-M Chen","year":"2023","unstructured":"Chen, W.-M. et al. Nrf3 promotes the proliferation and migration of triple\u2011negative breast cancer by activating PI3K\/AKT\/mTOR and epithelial\u2011mesenchymal transition. Oncol. Lett. 26, 443 (2023).","journal-title":"Oncol. Lett."},{"key":"76385_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.106045","volume":"26","author":"S Hirose","year":"2023","unstructured":"Hirose, S. et al. NRF3 activates mTORC1 arginine-dependently for cancer cell viability. iScience 26, 106045 (2023).","journal-title":"iScience"},{"key":"76385_CR61","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1158\/1541-7786.MCR-23-0034","volume":"21","author":"LJ Stanland","year":"2023","unstructured":"Stanland, L. J. et al. CBF-beta mitigates PI3K-alpha-specific inhibitor killing through PIM1 in PIK3CA-mutant gastric cancer. Mol. Cancer Res. 21, 1148\u20131162 (2023).","journal-title":"Mol. Cancer Res."},{"key":"76385_CR62","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1158\/0008-5472.CAN-22-2525","volume":"83","author":"N Malik","year":"2023","unstructured":"Malik, N. et al. Dysregulation of mitochondrial translation caused by CBFB deficiency cooperates with mutant PIK3CA and is a vulnerability in breast cancer. Cancer Res. 83, 1280\u20131298 (2023).","journal-title":"Cancer Res."},{"key":"76385_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2834","volume":"13","author":"B Keam","year":"2011","unstructured":"Keam, B. et al. Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Breast Cancer Res. 13, R22 (2011).","journal-title":"Breast Cancer Res."},{"key":"76385_CR64","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/s42003-020-1042-x","volume":"3","author":"P Savage","year":"2020","unstructured":"Savage, P. et al. Chemogenomic profiling of breast cancer patient-derived xenografts reveals targetable vulnerabilities for difficult-to-treat tumors. Commun. Biol. 3, 310 (2020).","journal-title":"Commun. Biol."},{"key":"76385_CR65","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401\u2013404 (2012).","journal-title":"Cancer Discov."},{"key":"76385_CR66","doi-asserted-by":"publisher","first-page":"l1","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, l1 (2013).","journal-title":"Sci. Signal."},{"key":"76385_CR67","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.c.6960535.v1","author":"I de Bruijn","year":"2023","unstructured":"de Bruijn, I. et al. Data from analysis and visualization of longitudinal genomic and clinical data from the AACR Project GENIE Biopharma Collaborative in cBioPortal. Am. Assoc. Cancer Res. https:\/\/doi.org\/10.1158\/0008-5472.c.6960535.v1 (2023).","journal-title":"Am. Assoc. Cancer Res."},{"key":"76385_CR68","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41587-020-0546-8","volume":"38","author":"MJ Goldman","year":"2020","unstructured":"Goldman, M. J. et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat. Biotechnol. 38, 675\u2013678 (2020).","journal-title":"Nat. Biotechnol."},{"key":"76385_CR69","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.cell.2015.11.062","volume":"164","author":"R Marcotte","year":"2016","unstructured":"Marcotte, R. et al. Functional genomic landscape of human breast cancer drivers, vulnerabilities, and resistance. Cell 164, 293\u2013309 (2016).","journal-title":"Cell"},{"key":"76385_CR70","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nbt.3519","volume":"34","author":"NL Bray","year":"2016","unstructured":"Bray, N. L., Pimentel, H., Melsted, P. & Pachter, L. Near-optimal probabilistic RNA-seq quantification. Nat. Biotechnol. 34, 525\u2013527 (2016).","journal-title":"Nat. Biotechnol."},{"key":"76385_CR71","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1038\/nm.3954","volume":"21","author":"H Gao","year":"2015","unstructured":"Gao, H. et al. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. Nat. Med. 21, 1318\u20131325 (2015).","journal-title":"Nat. Med."},{"key":"76385_CR72","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).","journal-title":"Nucleic Acids Res."},{"key":"76385_CR73","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/s41586-025-08592-0","volume":"640","author":"M Feuermann","year":"2025","unstructured":"Feuermann, M. et al. A compendium of human gene functions derived from evolutionary modelling. Nature 640, 146\u2013154 (2025).","journal-title":"Nature"},{"key":"76385_CR74","doi-asserted-by":"publisher","first-page":"3086","DOI":"10.1158\/0008-5472.CAN-24-0890","volume":"84","author":"R Shrestha","year":"2024","unstructured":"Shrestha, R. et al. An atlas of accessible chromatin in advanced prostate cancer reveals the epigenetic evolution during tumor progression. Cancer Res. 84, 3086\u20133100 (2024).","journal-title":"Cancer Res."},{"key":"76385_CR75","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.molcel.2010.05.004","volume":"38","author":"S Heinz","year":"2010","unstructured":"Heinz, S. et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol. Cell 38, 576\u2013589 (2010).","journal-title":"Mol. Cell"},{"key":"76385_CR76","doi-asserted-by":"publisher","first-page":"4756","DOI":"10.1093\/nar\/gkaa179","volume":"48","author":"M Takaku","year":"2020","unstructured":"Takaku, M., Grimm, S. A., De Kumar, B., Bennett, B. D. & Wade, P. A. Cancer-specific mutation of GATA3 disrupts the transcriptional regulatory network governed by Estrogen Receptor alpha, FOXA1 and GATA3. Nucleic Acids Res. 48, 4756\u20134768 (2020).","journal-title":"Nucleic Acids Res."},{"key":"76385_CR77","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1093\/jnci\/djr393","volume":"103","author":"M Dowsett","year":"2011","unstructured":"Dowsett, M. et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J. Natl. Cancer Inst. 103, 1656\u20131664 (2011).","journal-title":"J. Natl. Cancer Inst."},{"key":"76385_CR78","unstructured":"Komsta, L. & Novomestky, F. moments: Moments, Cumulants, Skewness, Kurtosis and Related Tests. https:\/\/CRAN.R-project.org\/package=moments (R Package Version 0.14.1, 2022)."},{"key":"76385_CR79","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3612","volume":"4","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara, K. et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat. Commun. 4, 2612 (2013).","journal-title":"Nat. Commun."},{"key":"76385_CR80","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9971","volume":"6","author":"D Aran","year":"2015","unstructured":"Aran, D., Sirota, M. & Butte, A. J. Systematic pan-cancer analysis of tumour purity. Nat. Commun. 6, 8971 (2015).","journal-title":"Nat. Commun."},{"key":"76385_CR81","doi-asserted-by":"publisher","first-page":"R110","DOI":"10.1186\/gb-2013-14-10-r110","volume":"14","author":"A Daemen","year":"2013","unstructured":"Daemen, A. et al. Modeling precision treatment of breast cancer. Genome Biol. 14, R110 (2013).","journal-title":"Genome Biol."},{"key":"76385_CR82","doi-asserted-by":"publisher","first-page":"D955","DOI":"10.1093\/nar\/gks1111","volume":"41","author":"W Yang","year":"2012","unstructured":"Yang, W. et al. Genomics of drug sensitivity in cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 41, D955\u2013D961 (2012).","journal-title":"Nucleic Acids Res."},{"key":"76385_CR83","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1038\/s41467-019-09940-1","volume":"10","author":"G Picco","year":"2019","unstructured":"Picco, G. et al. Functional linkage of gene fusions to cancer cell fitness assessed by pharmacological and CRISPR-Cas9 screening. Nat. Commun. 10, 2198 (2019).","journal-title":"Nat. Commun."},{"key":"76385_CR84","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/nchembio.1986","volume":"12","author":"MG Rees","year":"2016","unstructured":"Rees, M. G. et al. Correlating chemical sensitivity and basal gene expression reveals mechanism of action. Nat. Chem. Biol. 12, 109\u2013116 (2016).","journal-title":"Nat. Chem. Biol."},{"key":"76385_CR85","doi-asserted-by":"publisher","unstructured":"Bahl, S. A chromatin-informed transcriptional regulatory framework to stratify patients and guide therapy selection in triple-negative breast cancer. Code Ocean https:\/\/doi.org\/10.24433\/CO.3288699.v1.","DOI":"10.24433\/CO.3288699.v1"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76385-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76385-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76385-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:03:04Z","timestamp":1789603384000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76385-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":85,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["76385"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-76385-8","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,6]]},"assertion":[{"value":"15 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.D.-A. reports that at the time of publication, she was part of Tempus AI, Inc. D.W.C. reports consultancy and advisory relationships with AstraZeneca, Daiichi Sankyo, Exact Sciences, GenomeRx, Gilead, GlaxoSmithKline, Inivata\/NeoGenomics, Knight Therapeutics, Lilly, Merck, Novartis, Pfizer, Roche and SAGA; research funding to their institution from AstraZeneca, GenomeRx, Guardant Health, Grail, Gilead, GlaxoSmithKline, Inivata\/NeoGenomics, Knight, Merck, PearBio, Pfizer, ProteinQure, RayzeBio and Roche; and holds a holds a patent (US62\/675,228) for methods of treating cancers characterized by a high expression level of spindle and kinetochore associated complex subunit 3 (ska3) gene. M.J.E. reports honoraria from Novartis, Knight Therapeutics, and Roche. None of the patents are relevant to this work. The remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"9897"}}